TP53 and hematologic disorder: Progress has also been made in the development of stapled peptides, such as ALRN-6924, that inhibit both MDM2-p53 and MDM4-p53 interaction, which are under (pre-)clinical evaluation for hematological malignancies (NCT02264613) [166,167].